Inicio › Leucemia linfocítica crónica › Wisconsin › Milwaukee
Ensayos clínicos de Leucemia linfocítica crónica en Milwaukee, WI
14 estudios para Leucemia linfocítica crónica buscan participantes en centros de Milwaukee y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
ReclutandoFase 3
- Medical College of Wisconsin, Milwaukee
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutandoFase 3
- Medical College of Wisconsin, Milwaukee
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
ReclutandoFase 2
- The Medical College of Wisconsin, Milwaukee
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
ReclutandoFase 1
- Medical College of Wisconsin, Milwaukee
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- y 6 más
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutandoFase 1
- Medical College of Wisconsin, Milwaukee
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
ReclutandoFase 2
- Medical College of Wisconsin, Milwaukee
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutandoFase 4
- Medical College of Wisconsin, Milwaukee
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutandoFase 4
- Medical College of Wisconsin, Milwaukee
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
ReclutandoFase 1/2
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
Study of SGR-1505 in Mature B-Cell Neoplasms
ReclutandoFase 1
- Medical College of Wisconsin, Milwaukee
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
ReclutandoFase 1
- The Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
ReclutandoEstudio observacional
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
ReclutandoEstudio observacional
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee
Ensayos de Leucemia linfocítica crónica en otras ciudades
- Boston, MA31 estudios
- Columbus, OH29 estudios
- Durham, NC27 estudios
- Washington, DC22 estudios
- Seattle, WA21 estudios
- Rochester, MN19 estudios
- New York City, NY18 estudios
- Houston, TX17 estudios
- Baldwin Park, CA16 estudios
- Chicago, IL14 estudios
- Cincinnati, OH14 estudios
- Nashville, TN13 estudios
Otros estudios en Milwaukee
- Cáncer (todos los tipos)23 estudios
- Cáncer de seno23 estudios
- Cáncer de pulmón de células no pequeñas22 estudios
- Mieloma múltiple21 estudios
- Cáncer de pulmón21 estudios
- Cáncer de próstata20 estudios
- Linfoma folicular19 estudios
- Cáncer de páncreas18 estudios
- Linfoma no Hodgkin18 estudios
- Cáncer de ovario17 estudios
- Leucemia mielógena aguda17 estudios
- Linfoma de Burkitt16 estudios
De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.